284 related articles for article (PubMed ID: 25644286)
1. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
[TBL] [Abstract][Full Text] [Related]
2. Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.
Messaoudi K; Saulnier P; Boesen K; Benoit JP; Lagarce F
Int J Nanomedicine; 2014; 9():1479-90. PubMed ID: 24711698
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
Fourniols T; Randolph LD; Staub A; Vanvarenberg K; Leprince JG; Préat V; des Rieux A; Danhier F
J Control Release; 2015 Jul; 210():95-104. PubMed ID: 25982679
[TBL] [Abstract][Full Text] [Related]
4. EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro.
Resnier P; David S; Lautram N; Delcroix GJ; Clavreul A; Benoit JP; Passirani C
Int J Pharm; 2013 Oct; 454(2):748-55. PubMed ID: 23583841
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
6. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
8. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
9. Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
Saito R; Bringas JR; Panner A; Tamas M; Pieper RO; Berger MS; Bankiewicz KS
Cancer Res; 2004 Oct; 64(19):6858-62. PubMed ID: 15466173
[TBL] [Abstract][Full Text] [Related]
10. MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor.
Chen Y; Li R; Pan M; Shi Z; Yan W; Liu N; You Y; Zhang J; Wang X
J Neurooncol; 2017 Jul; 133(3):477-485. PubMed ID: 28501897
[TBL] [Abstract][Full Text] [Related]
11. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts.
Yokosawa M; Sonoda Y; Sugiyama S; Saito R; Yamashita Y; Nishihara M; Satoh T; Kumabe T; Yokoyama M; Tominaga T
Tohoku J Exp Med; 2010 Aug; 221(4):257-64. PubMed ID: 20622491
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
13. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells.
Kato T; Natsume A; Toda H; Iwamizu H; Sugita T; Hachisu R; Watanabe R; Yuki K; Motomura K; Bankiewicz K; Wakabayashi T
Gene Ther; 2010 Nov; 17(11):1363-71. PubMed ID: 20520650
[TBL] [Abstract][Full Text] [Related]
14. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Wang Z; Hu P; Tang F; Lian H; Chen X; Zhang Y; He X; Liu W; Xie C
Cancer Lett; 2016 Aug; 379(1):134-42. PubMed ID: 27267806
[TBL] [Abstract][Full Text] [Related]
15. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
[TBL] [Abstract][Full Text] [Related]
16. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
[TBL] [Abstract][Full Text] [Related]
17. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z
Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539
[TBL] [Abstract][Full Text] [Related]
18. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Le Mercier M; Mathieu V; Haibe-Kains B; Bontempi G; Mijatovic T; Decaestecker C; Kiss R; Lefranc F
J Neuropathol Exp Neurol; 2008 May; 67(5):456-69. PubMed ID: 18431251
[TBL] [Abstract][Full Text] [Related]
19. Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma.
Clavreul A; Roger E; Pourbaghi-Masouleh M; Lemaire L; Tétaud C; Menei P
Drug Deliv; 2018 Nov; 25(1):1756-1765. PubMed ID: 30338715
[TBL] [Abstract][Full Text] [Related]
20. Liposomal temozolomide drug delivery using convection enhanced delivery.
Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
